Reimagining the capabilities of traditional recording systems.
Delivering a familiar clinical process with clearer signals for EP procedures.
Redefining precision cardiac signal quality to improve the treatment of complex arrhythmia.
EP RECORDING. ENHANCED.
It’s time to upgrade the EP lab.
The ECGenius™ System represents an evolution in cardiac signal acquisition, interpretation and therapy support, creating unprecedented opportunities for the integration of artificial intelligence-driven analytic tools.
CathVision’s mission is to help physicians cure cardiac arrhythmia. Committed to empowering physicians to make more informed clinical decisions in the EP lab, CathVision is redefining the necessity of exceptional cardiac electrical signals to diagnose, characterize and treat the most common heart rhythm disorders. The company is focused on developing electrophysiology solutions centered around an innovative EP recording system and AI-based analytic tools.
CathVision began as a graduate-level clinical research project designed to determine necessary improvements to ablation therapy and was officially launched as a company in 2013 in Denmark. The company’s presence has since expanded to the United States with operations in Minnetonka, Minnesota.
The ECGenius™ System, CathVision’s unique high-fidelity, low-noise EP recording technology, earns FDA clearance.
CathVision enrolls patients in first U.S.-based clinical study at the University of Vermont Medical Center.
CathVision enrolls first patients in PVISION Multicenter Clinical Study at four European hospitals.
CathVision completes an investment round of €13M to begin multi-center clinical studies.
CathVision expands its board of directors and is awarded a €2.2M grant from the Horizon 2020 programs.
CathVision obtains IOS13485 certification and establishes a presence in the U.S.
CathVision closes its first multi-million-dollar round of funding.
CathVision is officially incorporated.